MEMBER'S AREA
GET IN TOUCH
JOIN US!

Previous ISCBH Meetings

1999
1st Conference
4-7 May 1999

Maastricht,
The Netherlands

2002
2nd Conference
12-15 June 2002

Sheffield,
UK

2005
3rd Conference
11-14 May 2005

Sorrento,
Italy

2007
4th Conference
21-24 June 2007

Montreal,
Canada

2009
5th Conference
23-26 June 2009

Cambridge,
UK

2013
6th Conference
22-25 June 2013

Rotterdam,
The Netherlands

2015
7th Conference
27-30 June 2015

Salzburg,
Austria

2017
8th Conference
10-13 June 2017

Würzburg,
Germany

2019
9th Conference
22.25 June 2019

Salzburg,
Austria

2022
10th Conference
2-5 July 2022

Dublin,
Ireland

2024
11th Conference
22-25 June 2024

Salzburg,
Austria

2026
12th Conference
26-30 June 2026

Montreal, Canada

International Conference on
Children’s Bone Health (ICCBH)

The International Conference on Children’s Bone Health (ICCBH) was started in 1999 by an international group of independent clinicians and researchers interested in bone metabolism and bone mass in children, adolescents, and young adults. Five conferences were organised successfully by members of the Organising Committee, the last being in Cambridge, UK, in 2009. In 2011 it was decided to approach an international association for administrative support and between 2013 and 2022 the European Calcified Tissue Society managed the ICCBH conferences on the Organising Committee’s behalf.

Some comments from previous ICCBH attendees:  

This conference was amazing, both in terms of speakers and organisation
One of the friendliest and best organised conferences I have ever attended
I spent four wonderful, inspiring, exciting days

Previous Meetings

Click on an image for more information

ICCBH 2020 Bone Disorder Meeting

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE